Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inga Odenholt

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 1997
Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteriaInga Odenholt, Elisabeth Löwdin, Otto Cars
The Journal of Antimicrobial Chemotherapy|November 26, 2004
Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimensInga Odenholt, Otto Cars, Elisabeth Löwdin
Antimicrobial Agents and Chemotherapy|September 25, 2003
Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacinInga Odenholt, Elisabeth Löwdin, Otto Cars
Antimicrobial Agents and Chemotherapy|July 11, 2007
Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic modelInga Odenholt, Elisabeth Löwdin, Otto Cars
Chemotherapy|June 28, 2007
Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficileInga Odenholt, Mats Walder, Marlene Wullt
Scandinavian Journal of Infectious Diseases|May 4, 2004
The use of CRP tests in patients with respiratory tract infections in primary care in Sweden can be questionedMalin André, Ake Schwan, Inga Odenholt, et al.
Scandinavian Journal of Infectious Diseases|April 11, 2003
Variation in the propensity to release endotoxin after cefuroxime exposure in different gram-negative bacteria: uniform and dose-dependent reduction by the addition of tobramycinGunilla Goscinski, Monica Lundholm, Inga Odenholt, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic modelInga Odenholt, Ingegerd Gustafsson, Elisabeth Löwdin, et al.
Scandinavian Journal of Infectious Diseases|September 5, 2003
Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trialMarlene Wullt, Marie-Louise Johansson Hagslätt, Inga Odenholt
Antimicrobial Agents and Chemotherapy|May 23, 2002
Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic modelInga Odenholt, Elisabeth Löwdin, Ingegerd Gustafsson, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 1997
Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteriaInga Odenholt, Elisabeth Löwdin, Otto Cars
The Journal of Antimicrobial Chemotherapy|November 26, 2004
Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimensInga Odenholt, Otto Cars, Elisabeth Löwdin
Antimicrobial Agents and Chemotherapy|September 25, 2003
Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacinInga Odenholt, Elisabeth Löwdin, Otto Cars
Antimicrobial Agents and Chemotherapy|July 11, 2007
Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic modelInga Odenholt, Elisabeth Löwdin, Otto Cars
Chemotherapy|June 28, 2007
Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficileInga Odenholt, Mats Walder, Marlene Wullt
Scandinavian Journal of Infectious Diseases|May 4, 2004
The use of CRP tests in patients with respiratory tract infections in primary care in Sweden can be questionedMalin André, Ake Schwan, Inga Odenholt, et al.
Scandinavian Journal of Infectious Diseases|April 11, 2003
Variation in the propensity to release endotoxin after cefuroxime exposure in different gram-negative bacteria: uniform and dose-dependent reduction by the addition of tobramycinGunilla Goscinski, Monica Lundholm, Inga Odenholt, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic modelInga Odenholt, Ingegerd Gustafsson, Elisabeth Löwdin, et al.
Scandinavian Journal of Infectious Diseases|September 5, 2003
Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trialMarlene Wullt, Marie-Louise Johansson Hagslätt, Inga Odenholt
Antimicrobial Agents and Chemotherapy|May 23, 2002
Pharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic modelInga Odenholt, Elisabeth Löwdin, Ingegerd Gustafsson, et al.
Pageof 5